β-Adrenoceptor antagonists in elderly patients with heart failure: A critical review of their efficacy and tolerability

Drugs and Aging

Volumn 24, Issue 12, 2007, Pages 1031-1044

  Dobre, Daniela ^a,b   Haaijer Ruskamp, Flora M ^a   Voors, Adriaan A ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Department of Clinical Pharmacology ^*  (Netherlands)

Author keywords

Beta adrenergic receptor antagonists, therapeutic use; Bisoprolol, therapeutic use; Bucindolol, therapeutic use; Carvedilol, therapeutic use; Elderly; Heart failure, treatment; Metoprolol, therapeutic use; Research and development

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; NEBIVOLOL;

AGED; BRADYCARDIA; CARDIOMYOPATHY; CLINICAL TRIAL; COMORBIDITY; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MORTALITY; OBSERVATIONAL STUDY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SEXUAL DYSFUNCTION; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 36348986615     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724120-00006     Document Type: Review

References (81)

1. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997; 18 (2): 208-25
2. Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22 (4 Suppl. A): 6A-13A
3. Kupari M, Lindroos M, Iivanainen AM, et al. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med 1997; 241 (5): 387-94
4. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 1999; 20 (6): 447-55
5. Nielsen OW, Hilden J, Larsen CT, et al. Cross sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. Heart 2001; 86 (2): 172-8
6. Bonneux L, Looman CW, Barendregt JJ, et al. Regression analysis of recent changes in cardiovascular morbidity and mortality in The Netherlands. BMJ 1997; 314 (7083): 789-92
7. Reitsma JB, Dalstra JA, Bonsel GJ, et al. Cardiovascular disease in the Netherlands, 1975 to 1995: decline in mortality, but increasing numbers of patients with chronic conditions. Heart 1999; 82 (1): 52-6
8. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000; 83 (5): 505-10
9. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98 (21): 2282-9
10. Cleland JG. Improving patient outcomes in heart failure: evidence and barriers. Heart 2000; 84 Suppl. 1: i8-10
11. Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002; 23 (23): 1867-76
12. Rector TS, Tschumperlin LK, Kubo SH, et al. Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail 1995; 1 (3): 201-6
13. Lenfant C. Report of the Task Force on Research in Heart Failure. Circulation 1994; 90 (3): 1118-23
14. Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002; 4 (3): 361-71
15. Florea VG. Classifying systolic and diastolic heart failure. JAMA 2007; 297 (10): 1058-9
16. Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344 (1): 17-22
17. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003; 107 (12): 1570-5
18. Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003; 41 (2): 217-23
19. Pernenkil R, Vinson JM, Shah AS, et al. Course and prognosis in patients > or = 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol 1997; 79 (2): 216-9
20. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45 (4): 525-30
21. Weber KT, Brilla CG, Janicki JS, et al. Myocardial fibrosis: role of ventricular systolic pressure, arterial hypertension, and circulating hormones. Basic Res Cardiol 1991; 86 Suppl. 3: 25-31
22. Lauer MS, Anderson KM, Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol 1991; 18 (5): 1287-94
23. Petrie MC, Hogg K, Caruana L, et al. Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: is there a reliable echocardiographic measure of diastolic dysfunction? Heart 2004; 90 (5): 511-7
24. Senni M, Redfield MM. Heart failure with preserved systolic function: a different natural history? J Am Coll Cardiol 2001; 38 (5): 1277-82
25. Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003; 41 (9): 1510-8
26. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355 (3): 251-9
27. Ali Raza J, Movahed A. Use of cardiovascular medications in the elderly. Int J Cardiol 2002; 85 (2-3): 203-15
28. Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 3 (4): 469-79
29. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe: part 2. Treatment. Eur Heart J 2003; 24 (5): 464-74
30. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26 (11): 1115-40
31. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001; 134 (7): 550-60
32. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98 (12): 1184-91
33. Dobre D, van Jaarsveld CH, Dejongste MJ, et al. The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2007; 16 (2): 152-9
34. Dobre D, van Jaarsveld CH, Ranchor AV, et al. Evidence-based treatment and quality of life in heart failure. J Eval Clin Pract 2006; 12 (3): 334-40
35. Willenheimer R, Van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112 (16): 2426-35
36. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001; 3 (3): 351-7
37. Deedwania PC, Gottlieb S, Ghali JK, et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004; 25 (15): 1300-9
38. Dulin BR, Haas SJ, Abraham WT, et al. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol 2005; 95 (7): 896-8
39. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med; 2001; 344: 1659-67
40. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334 (21): 1349-55
41. The CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13
42. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344 (22): 1651-8
43. MERIT-HF Study Group. Effect of metoprolol CR/XL randomised intervention trial in congestive heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7
44. Allada CS, Keogh AM, Kotlyar E, et al. Carvedilol in elderly heart failure patients. J Am Coll Cardiol 2002; 39 Suppl. A: 1113-46
45. Dulin BR, Haas SJ, Abraham WT, et al. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol 2005 Apr; 95 (7): 896-8
46. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002; 287 (7): 883-9
47. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362 (9377): 7-13
48. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001; 103 (10): 1428-33
49. Fung JW, Chan SK, Yeung LY, et al. Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. Eur J Heart Fail 2002; 4 (4): 489-94
50. Shibata MC, Flather MD, Bohm M, et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS): rationale and design. Int J Cardiol 2002; 86 (1): 77-85
51. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26 (3): 215-25
52. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin- converting enzyme inhibitors. Am J Cardiol 1997; 80 (2): 207-9
53. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 2002; 113 (8): 650-6
54. Johnson D, Jin Y, Quan H, et al. Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. J Am Coll Cardiol 2003; 42 (8): 1438-45
55. Chan JD, Rea TD, Smith NL, et al. Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). Am Heart J 2005; 150 (3): 464-70
56. Tandon P, McAlister FA, Tsuyuki RT, et al. The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. Arch Intern Med 2004; 164 (7): 769-74
57. Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004; 25 (14): 1214-20
58. Dobre D, DeJongste MJL, Lucas C, et al. Effectiveness of beta blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age? Br J Clin Pharmacol 2007; 63 (3): 356-64
59. Shlipak MG, Browner WS, Noguchi H, et al. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med 2001; 110 (6): 425-33
60. Dobre D, Van Veldhuisen DJ, Dejongste MJ, et al. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction: clinical implications and survival. Eur J Heart Fail 2007; 9 (3): 280-6
61. McAlister FA, Ezekowitz J, Tonelli M, et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109 (8): 1004-9
62. Ko DT, Hebert PR, Coffey CS, et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med 2004; 164 (13): 1389-94
63. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288 (3): 351-7
64. Baxter AJ, Spensley A, Hildreth A, et al. Beta blockers in older persons with heart failure: tolerability and impact on quality of life. Heart 2002; 88 (6): 611-4
65. Krum H, Hill J, Fruhwald F, et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. Eur J Heart Fail 2006; 8 (3): 302-7
66. Macdonald PS, Keogh AM, Aboyoun CL, et al. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999; 33 (4): 924-31
67. Mehta PA, McDonagh S, Poole-Wilson PA, et al. Heart failure in a district general hospital: are target doses of beta-blockers realistic? QJM 2004; 97 (3): 133-9
68. Maggioni AP, Sinagra G, Opasich C, et al. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart 2003; 89 (3): 299-305
69. Estep JD, Mehta SK, Uddin F, et al. Beta-blocker therapy in patients with heart failure in the urban setting: moving beyond clinical trials. Am Heart J 2004; 148 (6): 958-63
70. Hori M, Kitabatake A, Tsutsui H, et al. Rationale and design of a randomized trial to assess the effects of beta-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (JDHF). J Card Fail 2005; 11 (7): 542-7
71. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II. Causal mechanisms and treatment. Circulation 2002; 105 (12): 1503-8
72. Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev 2002; 7: 17-27
73. Benedict CR, Weiner DH, Johnstone DE, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol 1993; 22 (4 Suppl. A): 146A-53A
74. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002; 359 (9302): 248-52
75. Radford MJ, Foody JM. How do observational studies expand the evidence base for therapy? JAMA 2001; 286 (10): 1228-30
76. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators. Circulation 1996; 94 (11): 2807-16
77. Dobre D, Van Veldhuisen D, Mordenti G, et al. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 2007; 154 (1): 109-15
78. Simon T, Mary-Krause M, Funck-Brentano C, et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Eur Heart J 2003; 24 (6): 552-9
79. Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERITHF). J Am Coll Cardiol 2002; 40 (3): 491-8
80. Lenzen MJ, Boersma E, Scholte Op Reimer WJ, et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J 2005; 26 (24): 2706-13
81. Anthonio RL, Van Veldhuisen DJ, Breekland A, et al. Beta-blocker titration failure is independent of severity of heart failure. Am J Cardiol 2000; 85 (4): 509-12, A11